Saturday 17 October 2026
Export HCAT’s income statement to Excel — free account
Health Catalyst, Inc.
HCAT Healthcare Health Information Services
Health Catalyst, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $311.1 million, up 1.48% from fiscal 2024. In the quarter to June 2026, revenue fell 12.7%, EPS grew 6.78%, free cash flow grew 64.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
1.73
0.07
−3.89%
Follow HCAT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.50 | 0.30 | 0.54 | 0.63 | |
P/FCF ratio |
22.35 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
535.20 | 4.98 | 16.85 | (432.27) | |
P/B ratio |
1.46 | 0.67 | 0.68 | 0.60 | |
Price to Tangible BV |
4.38 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.67 | 0.45 | 0.72 | 0.83 | |
EV/EBITDA |
22.32 | 11.39 | 62.48 | 0.00 | |
EV/Operating CF |
6.99 | 7.21 | 307.21 | (20.63) | |
EV/FCF |
29.95 | (50.38) | (10.81) | (7.83) | |
Quick Ratio |
1.58 | 1.56 | 1.73 | 1.73 | |
Current Ratio |
2.70 | 1.69 | 1.89 | 1.88 | |
Net Debt/EBITDA |
24.21 | 25.14 | 6.34 | (15.11) | |
Debt/Assets |
42.80% | 37.21% | 30.49% | 26.08% | |
Debt/Equity |
1.52 | 1.11 | 0.62 | 0.46 | |
Asset Turnover |
0.60 | 0.46 | 0.46 | 0.45 | |
Operating CF/Net income |
(0.01) | (0.17) | (0.11) | 0.02 | |
Capex/Depreciation |
(0.14) | (0.05) | (0.06) | (0.38) | |
Interest Coverage |
(9.75) | (25.75) | (18.85) | (3.74) | |
Research and Development Expense of Revenue |
15.64% | 13.82% | 13.27% | 16.09% | |
Selling, General and Administrative Expense of Revenue |
31.62% | 34.69% | 28.41% | 39.87% | |
Intangible Assets out of Total Assets |
0.19 | 0.44 | 0.57 | 0.64 | |
Share Based Compensation of Revenue |
3.84% | 5.33% | 5.50% | 9.22% | |
Graham Net Nets |
(0.06) | (1.00) | (0.52) | (0.45) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(184.92%) | (292.91%) | (106.28%) | (55.79%) | |
Free Cash Flow Yield |
4.47% | (2.94%) | (12.44%) | (16.68%) | |
Revenue per Share |
0.95 | 0.97 | 1.07 | 1.08 | |
Operating CF per Share |
0.00 | 0.26 | 0.14 | (0.01) | |
Capex per Share |
(0.07) | (0.08) | (0.08) | (0.07) | |
Free Cash Flow per Share |
(0.07) | 0.18 | 0.06 | (0.08) | |
Cash per Share |
1.40 | 1.50 | 1.37 | 1.30 | |
Shareholders Equity per Share |
1.36 | 1.90 | 3.52 | 4.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.36 | 1.90 | 3.52 | 4.72 | |
Free Cash Flow |
(5.17) | 13.02 | 4.33 | (5.59) | |
Working Capital |
156.47 | 74.70 | 79.73 | 77.46 | |
Capital Expenditures |
(5.45) | (5.49) | (5.58) | (5.13) | |
Net Current Asset Value |
(9.39) | (91.74) | (87.56) | (89.85) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.08 | 0.07 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
55.14 | 61.60 | 58.16 | 55.88 | |
Average Payables |
8.64 | 10.32 | 10.40 | 9.61 | |
Average Assets |
487.39 | 651.87 | 680.79 | 700.09 | |
Average Common Equity |
224.19 | 257.48 | 305.49 | 343.48 |
Columns are period end dates